Galectin Therapeutics to Present at BIO CEO & Investor Conference
February 08, 2017 08:30 ET
|
Galectin Therapeutics
NORCROSS, Ga., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold...
Galectin Therapeutics to Webcast Corporate Update At Annual Meeting of Stockholders
December 08, 2016 08:00 ET
|
Galectin Therapeutics
NORCROSS, Ga., Dec. 08, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company...
Mats Wahlström Joins Surefire Medical Board of Directors
November 30, 2016 06:00 ET
|
Surefire Medical, Inc.
WESTMINSTER, Colo., Nov. 30, 2016 (GLOBE NEWSWIRE) -- Surefire Medical, Inc. today announced that Mats Wahlström is joining the company’s Board of Directors and will serve as chairman. Wahlström...
Surefire Medical Receives Grant to Pursue Phase 1b Clinical Trial of CAR-T Immunotherapy Delivery through Precision Infusion System
November 15, 2016 06:00 ET
|
Surefire Medical, Inc.
WESTMINSTER, Colo., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Surefire Medical, Inc. announced a grant from the Colorado Office of Economic Development and International Trade (OEDIT) to initiate...
Daiichi Sankyo and ArQule Announce Continuation of METIV-HCC Phase 3 Study of Tivantinib in Second-Line Hepatocellular Carcinoma
Independent Data Monitoring Committee (DMC) Conducts Interim Assessment BURLINGTON, Mass. and PARSIPPANY, N.J., March 22, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) and Daiichi Sankyo...
Dendritic Cell Vaccine Inhibits Tumor Progression in Preclinical Liver Cancer Model
February 25, 2016 12:16 ET
|
Saronic Biotechnology, Inc.
NEW YORK, Feb. 25, 2016 (GLOBE NEWSWIRE) -- Saronic Biotechnology, Inc. today announces publication of preclinical data of autologous dendritic cell (DC) vaccine treatment in a murine model for...
Human Validation Data Supporting Saronic Biotechnology’s Lead Therapeutic SBI1997 Published in the Journal of Immunotherapy
February 09, 2016 11:10 ET
|
Saronic Biotechnology, Inc.
NEW YORK, Feb. 09, 2016 (GLOBE NEWSWIRE) -- Saronic Biotechnology, Inc., a U.S. biotechnology company dedicated to developing novel immunotherapeutics for liver cancer, today announces the...
ArQule Presents Clinical Biomarker Data From Phase 2 Study and Ongoing Phase 3 METIV-HCC Study of Tivantinib in Second-Line Hepatocellular Carcinoma at the 2016 Gastrointestinal Cancers Symposium
January 25, 2016 07:30 ET
|
ArQule, Inc.
Preliminary analysis of baseline MET incidence in METIV-HCC trial confirms results observed in phase 2 trial BURLINGTON, Mass., Jan. 25, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL)...
Saronic Biotechnology Files Investigational New Drug Application With FDA for SBI1997 Phase I/II Clinical Trial
December 18, 2015 10:20 ET
|
Saronic Biotechnology, Inc.
NEW YORK, Dec. 18, 2015 (GLOBE NEWSWIRE) -- Saronic Biotechnology, Inc. announces the filing of an Investigational New Drug application with the United States Food and Drug Administration (FDA) for...
OnCore Biopharma Announces Exclusive HBV Research Collaboration With the Baruch S. Blumberg Institute
November 19, 2014 07:00 ET
|
OnCore Biopharma, Inc.
DOYLESTOWN, Pa., Nov. 19, 2014 (GLOBE NEWSWIRE) -- OnCore Biopharma, Inc. ("OnCore" or the "Company"), a biopharmaceutical company focused on the research, development and commercialization of oral...